Findlay Park Partners LLP Has $122.27 Million Stake in The Cooper Companies, Inc. $COO

Findlay Park Partners LLP cut its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 1.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,783,400 shares of the medical device company’s stock after selling 32,500 shares during the quarter. Findlay Park Partners LLP owned about 0.90% of Cooper Companies worth $122,270,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. CYBER HORNET ETFs LLC bought a new position in Cooper Companies during the second quarter worth $36,000. MUFG Securities EMEA plc acquired a new stake in shares of Cooper Companies during the 2nd quarter worth about $42,000. Assetmark Inc. boosted its holdings in shares of Cooper Companies by 357.8% during the 2nd quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock worth $44,000 after buying an additional 483 shares during the period. Quent Capital LLC bought a new stake in shares of Cooper Companies during the 3rd quarter worth about $44,000. Finally, Mather Group LLC. acquired a new position in Cooper Companies in the 3rd quarter valued at about $56,000. Institutional investors own 24.39% of the company’s stock.

Insider Transactions at Cooper Companies

In other news, Director Maria Rivas purchased 1,000 shares of Cooper Companies stock in a transaction that occurred on Thursday, December 18th. The shares were acquired at an average price of $82.13 per share, for a total transaction of $82,130.00. Following the transaction, the director owned 11,141 shares of the company’s stock, valued at approximately $915,010.33. The trade was a 9.86% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Lawrence Erik Kurzius acquired 2,000 shares of the stock in a transaction on Wednesday, December 17th. The shares were purchased at an average price of $82.50 per share, with a total value of $165,000.00. Following the completion of the transaction, the director owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. This represents a 34.62% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders purchased 16,014 shares of company stock worth $1,304,416. Corporate insiders own 1.98% of the company’s stock.

Cooper Companies Price Performance

Cooper Companies stock opened at $83.67 on Friday. The firm has a market cap of $16.32 billion, a PE ratio of 44.51, a price-to-earnings-growth ratio of 2.40 and a beta of 1.03. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The stock’s fifty day moving average price is $82.27 and its two-hundred day moving average price is $75.70. The Cooper Companies, Inc. has a one year low of $61.78 and a one year high of $92.84.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.04. The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.Cooper Companies’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.04 EPS. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, research analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on COO. JPMorgan Chase & Co. raised their price objective on shares of Cooper Companies from $66.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, December 5th. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a report on Friday, December 5th. Robert W. Baird boosted their price target on Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research note on Friday, December 5th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $73.00 price objective on shares of Cooper Companies in a report on Friday, January 9th. Finally, Piper Sandler reissued an “overweight” rating and set a $94.00 target price (up from $83.00) on shares of Cooper Companies in a report on Friday, December 5th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $90.77.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.